Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial

[1]  M. Drayson,et al.  A population‐based study of the impact of dialysis on mortality in multiple myeloma , 2018, British journal of haematology.

[2]  B. Pégourié,et al.  Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial , 2017, JAMA.

[3]  H. Goldschmidt,et al.  International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Dimopoulos,et al.  Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis , 2016, American journal of hematology.

[5]  D. Niederwieser,et al.  Successful Treatment with Bortezomib in Combination with Bendamustine and Prednisone of Patients with Newly Diagnosed/Untreated Multiple Myeloma and Light Chain Induced Renal Failure , 2011 .

[6]  Cohen,et al.  A351 Serum FLC Levels Can Be Reduced Rapidly; Lower Levels Are Associated with Renal Recovery , 2009 .

[7]  N. Heyne,et al.  European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial , 2008, Trials.

[8]  T. Economopoulos,et al.  Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance , 2007, Leukemia & lymphoma.

[9]  G. Morgan,et al.  Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  V. Gandhi.  Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. , 2002, Seminars in oncology.

[11]  R. Soutar,et al.  Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. , 1999, Blood reviews.

[12]  S. Montoto,et al.  Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. , 1998, Archives of internal medicine.

[13]  E. Montserrat,et al.  Patients with multiple myeloma requiring long‐term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases , 1995, British journal of haematology.

[14]  E. Holmberg,et al.  Renal function in newly diagnosed multiple myeloma — A demographic study of 1353 patients , 1994, European journal of haematology.